Illumina's NGS-based prenatal test offering swells with Verinata buy
This article was originally published in Clinica
Executive Summary
Genome sequencing specialist Illumina has agreed to acquire Verinata Health, which specialises in noninvasive tests for identifying foetal chromosomal abnormalities, expanding its reach in the area of next-generation sequencing-based diagnostics.